Drugs in ATC Class C05A

Up to Top Level ATC Classes

Up to C - Cardiovascular system

Up to C05 - VASOPROTECTIVES

Subclasses in ATC: C05A - AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE

C05AA - Corticosteroids

C05AD - Local anesthetics

C05AE - Muscle relaxants

C05AX - Other agents for treatment of hemorrhoids and anal fissures for topical use

C05A Market Analysis and Financial Projection

The market and patent landscape for ATC Class C05A (Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use) reflects dynamic growth driven by rising disease prevalence and innovation. Here’s a breakdown of key trends and developments:

---

Market Dynamics

Growth Drivers

• Rising Disease Burden: Anal fissures and hemorrhoids are increasingly common due to factors like sedentary lifestyles, constipation, and aging populations. The global anal fissure treatment market was valued at $1.04 billion in 2023, projected to reach $1.49 billion by 2030 (CAGR: 5.3%)[6][14].
• Regional Dominance: North America holds over 41% market share (2023), driven by advanced healthcare infrastructure, while Asia-Pacific shows rapid growth due to rising healthcare investments[6][14].
• Product Innovation: Key players like AbbVie, Novartis, and Teva focus on novel formulations. For example, Acrux Limited’s Nitroglycerin Ointment (0.4%) targets chronic anal fissure pain and is under FDA review[14].

Segmentation

• By Drug Class:	Subgroup	Key Components
  Corticosteroids	Hydrocortisone, prednisolone
  Antibiotics	Metronidazole, antifungals
  Local Anesthetics	Lidocaine, benzocaine
  Muscle Relaxants	Glyceryl trinitrate, isosorbide dinitrate

• Topical Nitrates like glyceryl trinitrate dominate due to efficacy in reducing sphincter hypertonia[8][11].

---

Patent Landscape

Key Innovations

1. Formulation Advances:
   • US11865207 (2024): Ferring B.V.’s mucoadhesive polymer-based composition for anal fissures and hemorrhoids[3][15].
   • US20220151918A1 (2022): Thiomer polymer and propylene glycol formulation to enhance drug retention[15].
2. Novel Mechanisms:
   • Anticoagulants (e.g., heparin) for hemorrhoid treatment (EP3834831A1)[13].
   • Macrocyclic lactones targeting inflammation (US20130178433A1)[16].
3. Combination Therapies: Patents increasingly cover multi-ingredient products (e.g., corticosteroids + local anesthetics)[12][14].

Strategic Trends

• Freedom-to-Operate (FTO) Analyses: Critical for navigating a crowded patent space, especially with overlapping claims in ADC-like combination therapies[2].
• Licensing and Litigation: Example: Genentech licensed Immunogen’s emtansine technology for Trastuzumab emtansine (Kadcyla®)[2].

---

Competitive Landscape

• Top Players: L3Harris, Honeywell, and Thales lead in automation and communication systems for ATC[1][7], while AbbVie, Sanofi, and Boehringer Ingelheim dominate pharmaceuticals[6][14].
• R&D Focus: Shift toward sustained-release formulations and minimally invasive therapies (e.g., botulinum toxin injections)[6][11].

---

Regional Insights

• North America: Leads in patent filings (e.g., ~4,000 CTC patents)[10], driven by R&D investment.
• Europe: Strong in regulatory-compliant innovations (e.g., vedotin analogs)[2].
• Asia-Pacific: Emerging as a hub for cost-effective generic production[6][14].

---

Challenges and Opportunities

• Regulatory Hurdles: Strict FDA/EMA guidelines for topical drug safety and efficacy[4][12].
• Sustainability Trends: Demand for eco-friendly manufacturing processes in ATC equipment[9].
• Digital Health Integration: AI-driven ATC systems and telemedicine for anal disorder management[7][9].

---

Key Takeaway: The C05A market is poised for growth, fueled by innovation in drug formulations and strategic IP management. Companies must balance patent litigation risks with collaborative R&D to capitalize on unmet needs in hemorrhoid and anal fissure treatment.

References

1. https://www.fortunebusinessinsights.com/air-traffic-control-atc-market-102957
2. https://www.fbrice.com.au/ip-news-insights/traversing-a-dynamic-adc-patent-landscape-2/
3. https://patents.justia.com/patents-by-us-classification/514/882
4. https://atcddd.fhi.no/filearchive/publications/2025_guidelines__final_web.pdf
5. https://patentimages.storage.googleapis.com/51/55/13/f83dd699852cbc/US8987292.pdf
6. https://www.coherentmarketinsights.com/industry-reports/anal-fissure-treatment-market
7. https://www.stellarmr.com/report/Air-Traffic-Control-ATC-Communications-Market/1805
8. https://pubmed.ncbi.nlm.nih.gov/7736873/
9. https://github.com/supashcriana/Market-Research-Report-List-1/blob/main/air-traffic-control-equipment-atc-market.md
10. https://www.globenewswire.com/news-release/2024/11/12/2979157/28124/en/Circulating-Tumor-Cells-Patent-Landscape-and-Forecast-2024-2032-The-U-S-Leads-with-Over-4-000-Patent-Filings-Driven-by-Robust-R-D-Infrastructure-and-Substantial-Investments-in-Canc.html
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC11541248/
12. https://atcddd.fhi.no/atc_ddd_index/?code=C05A&showdescription=yes
13. https://patents.google.com/patent/EP3834831A1/en
14. https://www.thebusinessresearchcompany.com/report/anal-fissure-treatment-global-market-report
15. https://patents.google.com/patent/US20220151918A1/en
16. https://eureka.patsnap.com/patent-US20130178433A1